

Retatrutide 20 mg

RT-2026-033 Lot NOT PROVIDED Analyzed October 28, 2026



TIMELINE	SAMPLE	TESTING
ORDERED	NAME	CLIENT
October 20, 2026	Retatrutide 20 mg	HealLabs
RECEIVED	EXPECTED	TEST TYPE
October 22, 2026	Retatrutide	Content & purity
ANALYZED	AMOUNT	METHOD
October 28, 2026	1 vial, lyophilized powder	HPLC-UV

CONTENT, HOW MUCH IS IN IT

Not detected

Label claim: 20 mg


IDENTITY, WHAT IT IS

Not detected

No retatrutide detected in either of two injections

CHROMATOGRAM

HPLC-UV



ANALYST COMMENTS

White lyophilized powder, white-cap vial, received sealed. The sample was injected twice, the second time at ten times the normal load, and retatrutide was not found in either injection (detection limit about 0.02 mg per vial). The dashed traces show the first injection and a retatrutide reference run on the same method, marking where retatrutide elutes. The only significant peak is an early eluting unidentified UV-absorbing component.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: October 28, 2026

VERIFICATION CODE

RT-0UK9-GYZH

Verify at purilab.org/verify/RT-0UK9-GYZH

SCAN TO VERIFY



RT-0UK9-GYZH

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.